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Abstract:
Objectives: This systemic review is conducted to compare between Percutaneous Coronary
Intervention (PCI) and Coronary Artery Bypass Graft (CABG) in the revascularization strategy
of patients with diabetes mellitus (DM) and multivessel coronary artery disease (CAD) based on
clinical outcomes.
Background: Diabetes mellitus approached epidemic proportions globally and was recognized
as a risk factor of aggressive and multivessel CAD [1,2]. The controversy over the optimal
revascularization strategy for patients with DM and multivessel CAD has been hotly debated for
more than 10 years. Numerous studies and data analysis were conducted to compare between
PCI and CABG based on clinical outcomes of DM patients after procedure. Those studies
enormously contributed to the improvement in long-term survival rate, major adverse cardiac
and cerebrovascular events (MACCE) rate, quality of life, and cost-effectiveness.
Methods: This systemic review utilized PubMed, ScienceDirect, and Google Scholar as search
engines. A total of 39 articles were recruited. Among them, 26 articles were analyzed and
organized based on timeline, where data about long-term survival rate, the MACCE rate, quality
of life, complications after both procedures were extracted and conclusions were made.
Results: In the bare-metal stent era, CABG showed better outcomes compared with PCI for both
short- and long-term clinical outcomes. Patients who underwent PCI had significantly higher
mortality rate, MACCE rate, and repeated revascularization rate compared with patients who
underwent CABG. However, with the advent of drug-eluting stent, PCI became comparable to
CABG especially in short-term outcomes. Nonetheless, CABG still surpassed PCI in the long
run with smaller mortality, myocardial infarction (MI) rate, and repeated revascularization risk at
five-year follow-up. Hence, CABG remains the revascularization strategy of choice for patients
with DM and multivessel CAD.
Conclusion: Although patients who underwent CABG face higher risk of stroke compared to
patients who underwent PCI, CABG outweighs PCI with the reduced mortality, MI rate and
repeated revascularization rate, especially in long-term follow-up. Supposing the decision
process depends on clinical judgment and accessibility to procedure, CABG should be preferable
in patients with DM and multivessel CAD.
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Percutaneous coronary intervention versus coronary artery bypass graft in the treatment
of multivessel coronary artery disease on Diabetes Mellitus patients

Introduction
The global prevalence of diabetes mellitus (DM) has almost doubled in the past three
decades, rising from 4.7% in 1980 to 8.5% in 2014. It has been considered a worldwide epidemic
of the 21st century [1,2]. Since DM patients have 2 to 4-fold increased mortality risk from
coronary artery disease (CAD), it is a major factor in determining long-term prognosis [3].
Furthermore, a large percentage of diabetic patients display multivessel CAD due to the systemic
nature of atherosclerotic process in DM [4]. The connection between diabetes and CAD can be
justified by the following mechanisms. Firstly, high blood sugar level stimulates the expression
of glycoprotein IIb/IIIa on the platelets surface, leading to the elevated aggregation [5]. Second,
several inflammatory factors and adhesion molecules thrive in diabetic patients including Creactive protein, tumor necrosis factor, CD40, vascular cell adhesion molecule-1, and
intercellular adhesion molecule [6]. Finally, many diabetic patients concurrently have metabolic
disorders and cardiovascular comorbidities such as hyperlipidemia, obesity, hypertension, heart
failure, etc. Therefore, diabetes accelerates the endothelial dysfunction and the diffuse
atherosclerosis process leading to a high rate of multivessel CAD or left main coronary disease.
Despite advances anti-thrombotic drug therapy and revascularization methods, Percutaneous
coronary intervention (PCI) and Coronary artery bypass graft (CABG) remain the treatment of
choice for patients with diabetes and multivessel CAD. The long-standing debate over the
optimal revascularization strategy for patients with diabetes and multivessel CAD has continued
to be a vibrant discussion topic for more than 10 years.
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Over the last decade, PCI technique has developed dramatically from bare-mental stents
to drug-eluting stents and pronouncedly improved patient outcomes. Thus, does CABG still is
preferred over PCI in revascularization for diabetic patients with multivessel CAD? This paper
intends to dive deeper into numerous clinical outcomes of diabetic patients with multivessel
CAD who underwent either PCI or CABG to answer this question. By guiding patients in the
decision process of their revascularization method, the importance of this paper is to improve
clinical outcomes such as mortality rate, MI and stroke rate, cost-effectiveness, quality of life,
etc.

Methods:
By utilizing different research tools such as PubMed, ScienceDirect, and Google Scholar,
this paper identified numerous studies comparing PCI and CABG in the treatment of multivessel
CAD on diabetic patients. Keywords that were used in the searching process included
“Percutaneous coronary intervention”, “Multivessel coronary artery disease”, “Diabetes type II”,
“Coronary artery bypass graft”, “Comparison”, “Survival rate”, “Cost-effectiveness”, “Quality of
life”, “Bare-metal stent”, “Drug-eluting stent”. There were three articles that examined baremental stent placement versus CABG, 23 articles specifically analyzed PCI with drug-eluting
stent versus CABG. All studies were no older than 15 years with the oldest study was published
in 2005. Most articles were dedicated to diabetic patients with multivessel CAD or at least had a
subgroup of diabetic patients. In addition, this paper prioritized applying randomized controlled
studies as its core. The reference lists of those trials were utilized as a systemic review to find
relevant studies to boost the validity of this meta-analysis (Appendix A).
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The major inclusion criteria included participants who were older than 18 years old from
both sexes, pre-existing DMII, angiographically confirmed multivessel CAD [ ≥70% occlusion in
≥

2 major epicardial vessels or in ≥ 2 separate coronary artery including left anterior descending

(LAD) artery, left circumflex (LCX) artery, and right coronary artery (RCA), eligible candidates
for both PCI and CABG. The major exclusion criteria included pre-existing congestive heart
failure (NYHA class III and IV or pulmonary edema), prior CABG surgery, prior cardiac valve
surgery, prior PCI or previous stroke within six months, history of hematologic disease,
suspected pregnancy, dementia. The author of this paper carefully reviewed all data and analyzed
all articles separately. After compare and contrast valuable studies, appropriate data and results
are extracted to ensure the coherence of this paper.

Background:
Percutaneous Coronary Intervention (PCI) is a nonsurgical procedure that is used to treat
occlusive coronary arteries found in CAD. PCI is combined of two main steps: coronary
angioplasty and stents placement. After accessing blood stream through peripheral artery, a
coronary catheterization is used to visualize the coronary arteries and angioplasty is performed
with a balloon catheter. The inflated balloon recaptures the occlusive coronary artery and a stent
is placed to keep the vessel open. According to ACC/AHA guidelines released in 2001, the
indications of PCI are diverse, varies from acute coronary syndrome to stable CAD [7]. Some of
the indications include acute ST- elevation myocardial infarction, non ST- elevation acute
coronary syndrome, left main coronary artery disease or left anterior descending disease, chronic
total occlusion, angina (stable and unstable), high risk surgical patients, positive stress test, and
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DMII with multivessel CAD. Therefore, PCI is widely applied now for patients with CAD,
varies from asymptomatic to moderately and severely symptomatic ones.
Stent in PCI is defined as a wire-meshed tube that keeps the vessel open. Stent can be
either drug-eluted or bare-metal. According to the book Essentials of Cardiac Anesthesia for
Noncardiac surgery of Emilio B. Lobato [8], bare-metal stents, which is the first stent using in
coronary stenting could be made from stainless steel, cobalt chromium, or platinum chromium.
First brought to the clinic in the 1990s, bare-metal stent successfully diminished the incidence of
the two most common periprocedural complications of coronary arteries revascularization
including restenosis and acute vessel closure, compared to balloon angioplasty. Hence, according
to Fischman et al.,[9] patients who underwent bare-mental stenting had higher successful
procedure rate and lower rate of restenosis than patients who underwent balloon angioplasty
(96.1% vs. 89.6% and 31.6% vs. 42.1%, respectively). The introduction of drug-eluting stents
into practice became a millstone of PCI technique evolution and contributed enormously to the
broad applications of this procedure in contemporary medicine. The stent slowly releases
antiproliferative agents such as paclitaxel and “limus” family. According to A randomized
comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
conducted by Morice et al.,[10] restenosis (50% or more of the luminal diameter) did not occur
on any sirolimus-stent patients participated in the study at six months after procedure. However,
it occurred on 26.6% patients in the bare-metal group. Furthermore, at one year follow-up, the
bare-metal group had significantly higher rate of major cardiac events compared to sirolimusstent group (28.8% vs. 5.8%, respectively). Thus, drug-eluting stent remarkably increase the
clinical outcomes of PCI procedure by preventing neointimal proliferation.
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CABG is a surgical procedure, which is also used in CAD treatment by reinstating blood
flow to the occlusive coronary arteries. The procedure has two main approaches. In the first one,
left internal thoracic artery is pedicled and rerouted into the left anterior descending coronary
artery. The second approach uses the great saphenous vein to connect between aorta and the
obstructed coronary artery. The 1999 ACC/AHA guidelines for CABG surgery listed various
indications including significant left main coronary artery stenosis (>70%), significant left
anterior ascending coronary artery stenosis (70%), three-vessel CAD, two-vessel CAD with left
anterior ascending coronary stenosis, disabling angina despite ultimate noninvasive therapy[11].
This procedure is mostly performed to relieve uncontrolled angina, prevent left coronary artery
dysfunction and death from myocardial infarction (MI).
Therefore, PCI and CABG share the same indication for diabetic patients with CAD. PCI
is preferable in patients who required urgent revascularization. However, the choice between PCI
and CABG on diabetic patients with multivessel CAD, who are belongs to the scope of this
paper is affected by numerous factors such as the number of occlusive coronary vessels, patients
comorbidities, the complexity of anatomy of the lesion, etc. Therefore, this topic remains as
highly debated.
In the bare-metal stent era, Serryus et al. [12] conducted one of the first randomized trials
to compare between stent implantation and CABG for multivessel disease, called the Arterial
Revascularization Therapy Study (ARTS-I trial). Between April 1997 and June 1998, 1205
diabetic and non-diabetic patients with multivessel CAD were enrolled and randomly assigned to
undergo either PCI with bare-metal stents or CABG. All patients were suitable candidates for
both procedures. Personal assessments including patient’s history, questionnaires about angina
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status, quality of life, hospital cost were performed after 30 days, six months, and 12 months of
post-procedure period. At 30 days after procedure, patients who underwent stent implantation
had higher risk of develop an MACCE (26.2%), compared to patients of CABG group (12.2%).
In fact, the MACCE rate, which was the combination of all-cause mortality, MI rate, stroke rate
and repeated revascularization, was a crucial endpoint in all of the studies belonging to the scope
of this paper. In addition, at 12 moths of post-procedure, 21.0 % of stenting group had to be
revascularized, only 3.8 % of the CABG group underwent another revascularization procedure
[8]. Furthermore, more patients from CABG group were relieved from angina, compared to
stenting group (90% vs. 79%, respectively). Patient used self-assessment EuroQoL questionnaire
as a tool to evaluate their quality of life. Scores were collected at one month, six months and 12
months after intervention. A significant better quality of life after PCI compared to CABG was
noticeable at one month (84±16 vs. 78± 17, respectively); meanwhile, there was no difference
after 6 months (86±16 in PCI and 86±15 in CABG). Patients in the CABG group experienced
slight better quality of life at 12 months (87±16 in CABG vs. 86±16in PCI). The cost of initial
procedure of CABG outpaced that of stent implantation for $4,212 more due to prolonged
hospitalization. On the other hand, because of the significant higher risk of repeated
revascularization, there was no important cost-effective disparity between CABG and PCI in the
long run.
Clinical and economic impact of diabetes mellitus on percutaneous and surgical
treatment of multivessel coronary disease patients: insights from the Arterial Revascularization
Therapy Study (ARTS) trial was conducted by Abizaid et al. [13], to examine the results of the
ARTS-I trial in the subgroup of diabetic patients, which accounted for 17.3% of total 1205
participants. The one-year clinical outcomes were noteworthy for the lowest MACCE-free
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survival rate of diabetic stenting group (63.4%), compared with both diabetic CABG group
(84.4%) and nondiabetic stenting group (76.2%). This finding demonstrated that diabetes was an
independent risk factor of 1-year MACCE after PCI procedure but not after CABG.
Interestingly, there was no critical difference in one-year event-free survival rate between
diabetic and non-diabetic group of patients who were treated with CABG (84.4% vs. 88.4%,
respectively). The total one-year cost of treatment in diabetic patients who underwent PCI was
$12,855 and who underwent CABG was $16,585. In nondiabetic group, one-year treatment cost
$10,164 for stenting and $ 13,082 for CABG. Therefore, the total one year cost of treatment in
CABG patients outranged that in PCI patients, regardless of diabetic status. Essentially, in
diabetic patients, the risk of repeated revascularization of stenting patients doubled that of CABG
patients (21.6% vs. 12.4%, respectively). This subgroup analysis revealed that CABG provides a
superior clinical outcomes at one year compared with PCI, especially in diabetic patients with
multivessel CAD.
Serryus et al.[14], continued to follow their participants of the ARTS-I trial and collected
various data in five years. Authors published a data analysis named Five-year outcomes after
coronary stenting versus bypass surgery for the treatment of multivessel disease: the final
analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial in 2005.
Among 208 diabetic patients, the mortality rate of those who were treated with stent implantation
was 13.8%, versus 8.3% in those who underwent CABG [10]. Diabetes was critically relevant to
risk of death within stenting group (13.4% death in diabetic group and 6.8% death in nondiabetic group) [10]. In contrast, there was no significant difference in 5-year mortality between
diabetic and non-diabetic group that both underwent CABG (8.3% vs. 7.5, respectively).
Furthermore, in stenting group, diabetic patients had higher rate of MACCE at 5 years of post-
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procedure than non-diabetic patients (54.5% vs. 38.7%, respectively) [10]. The rate of MACCE
at 5 years of diabetic group underwent CABG was similar with that of non-diabetic group
(25.0% vs. 21.2%, respectively). Although patients who chose CABG as their treatment were
older and had more co-comorbidity, their clinical outcomes continuously improved and became
better than that of PCI patients. Therefore, Serryus et al.[14], concluded that CABG remained as
a procedure of choice of revascularization on multivessel CAD, especially in diabetic patients.
After publishing the ARTS-I, Serryus et al.[15], began work on ARTS-II, the first
multicenter, non-randomized, stratified study comparing between drug-eluting stent implantation
vs. CABG on multivessel CAD. By using the surgical group of patients from the ARTS-I as
historical control, new patients with similar inclusion criteria were recruited and underwent PCI
with sirolimus-eluting stents. 607 patients of this ARTS-II arm were stratified to ensure that the
huge part of them had diabetes (26.2%) and multivessel CAD (53.5%). Clinical outcomes were
examined at 30 days and at one year after procedure and following data were drawn out. The
incidence of death and MACCE in ARTS-II population at 30 days was lower than that in ARTSI population (ARTS-I- CABG 5.5%, and ARTS-I-PCI 5.2%). There was no significant difference
in the one-year MACCE rate between ARTS-II population and ARTS-I-CABG (10.5% vs.
11.7%, respectively) [11]. However, ARTS-II patients still faced higher risk of repeated
revascularization, compared to the ARTS-I-CABG patients (8.5% vs. 4.2%, respectively) [11].
By revealing how sirolimus-eluting stents reduced the death and MACCE rate compared to baremental stenting, this study affirmed that PCI with drug-eluting stents had its efficacy and safety
in treatment of multivessel CAD patients.
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To investigate on the specific impact of the ARTS-II on diabetic patients, Macaya et
al.[16], conducted an analysis called One-year results of coronary revascularization in diabetic
patients with multivessel coronary artery disease. Sirolimus stent vs. coronary artery bypass
surgery and bare metal stent: insights from ARTS-II and ARTS-I based on its data and results.
The authors divided the ARTS-I and ARTS-II population into two groups of diabetic (367) and
non-diabetic patients (1445). They acknowledged two crucial outcomes. First, diabetics of the
ARTS-II trial demonstrated a comparable one-year MACCE rate with diabetics of the ARTS-ICABG trial (15.7% vs. 14.6%, respectively) regardless their increased complexity in CAD.
However, cerebrovascular events occurred more frequently in ARTS-I-CABG diabetics (5.2%)
than in ARTS-II diabetics (0%). As expected, the one year MACCE rate in ARTS-II diabetics
was significantly lower than that in ARTS-I-PCI diabetics (15.7% vs. 36.6%, respectively).
Second, in the ARTS-II population, diabetics surpassed non-diabetics in overall MACCE rate,
incidence of death, need for repeat revascularization (15.7% vs. 8.5%, 2.5% vs. 0.4%, and 12.5%
vs. 5.6%, respectively). This study depicted the phenomenal antirestenotic effect of sirolimuseluting stent through improvement in early outcomes, especially in diabetic patients.
Interestingly, CABG remains a preferable method of choice to prevent repeated
revascularization. Diabetes mellitus continue being defined as an independent risk factor for
MACCE after coronary revascularization. This sub-analysis of the main ARTS-I and ARTS-II
trials did not have large enough number of patients to provide a sufficient power. Another
potential bias could be attributed to long-term follow-up, in which clinical outcomes were
strongly affected by the improvement of medicine and technology. In addition, the differences
between the current ARTS-II population and the historical ARTS-I population required statistical
adjustment to avoid non-randomized study bias.
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Daemen et al.[17], continued to follow-up participants of the ARTS-II trial for 3 years
and specifically assigned them into diabetic and non-diabetic groups. In the non-diabetic group,
the MACCE in ARTS-II patients showed no distinct differences with ARTS-I-CABG patients
(16.3% vs. 15.8%, respectively), but was significantly lower than ARTS-I-PCI patients (16.3%vs
30.9%, respectively). The MACCE rate at 3-years in non-diabetic patients participated in the
ARTS-I and the ARTS-II trials experienced similar trends. Furthermore, the combined rate of
death from all-cause, nonfatal MI and nonfatal stroke in non-diabetic ARTS-II was significantly
lower than both non-diabetic ARTS-I-CABG and ARTS-I-PCI (7.8%, 10.3%, and 11.5%,
respectively). In the diabetic group, the MACCE rate of ARTS-II patients outstripped that of
ARTS-I-CABG (27.7% vs. 17.7%, respectively), but was not as high as that of ARTS-I-PCI
(27.7% vs. 47.3%, respectively). The combination of death from all-causes, nonfatal MI and
nonfatal stroke in ARTS-II patients remained slightly higher than all ARTS-I patients.
Another important trial conducted by Ong et al.[18], was a prospective, multicenter,
multinational randomized study called the SYNergy between percutaneous coronary intervention
with TAXus and cardiac surgery (SYNTAX) study. A total of 1800 patients who were
angiographically confirmed of de novo triple-vessels disease or left main disease were recruited
and randomly assigned to undergo either PCI with TAXUS Express paclitaxel-eluting stents or
CABG. Mack et al. [19], conducted a three-year follow-up of the SYNTAX trial called Bypass
versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic
syndrome, aiming patients with diabetes mellitus or metabolic syndrome. The MACCE rate of
PCI patients remarkably exceeded that of CABG patients, regardless the presence of diabetes.
This trend was also witnessed in the main endpoint of death/MI/stroke and in the risk of repeated
revascularization. However, diabetes recognized as a remarkable risk factor that significantly
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elevated the MACCE rate, mortality, and repeated revascularization risk for PCI arm, compared
with the CABG arm. For instant, in PCI group, the MACCE rate of diabetic patients accounted
for 37.0%, which was remarkably higher than that of non-diabetic patients. Meanwhile, in
CABG group, the MACCE rate of diabetic solely was slightly higher than that of non-diabetic
patients (p=0.264). The SYNTAX study has limitations since its primary endpoint was not met
due to the lost of participants. Therefore, the result of this subgroup analysis solely had
observational and hypothesis generating meaning.
Diabetic and Nondiabetic Patients with Left Main and/or 3-vessel Coronary Artery
Disease conducted by Banning et al.[20], was another comparison of the SYNTAX trial’s
outcomes on diabetic vs. non-diabetic group at one-year follow-up. In diabetic patients, the oneyear MACCE rate pronouncedly elevated after PCI treatment compared with CABG treatment
(26.0% vs. 14.2%, respectively). In non-diabetic patients, the 1-year MACCE rate was slightly
but not significantly higher in the PCI group compared with the CABG group (15.1% vs. 11.8%,
respectively). The combined of mortality, MI, and stroke rate was similar between CABG group
and PCI group despite diabetes status of patients. In regard to death rate, diabetic group always
exceeded non-diabetic group after either treatments. In addition, risk of stroke in CABG group
significantly higher than PCI group regardless diabetes status of patients. Risk of repeated
revascularization displayed an opposite trend where PCI group always surpassed CABG group in
both diabetic and non-diabetic patients. The study had several significant limitations. First, one
year follow-up could not reflect completely the difference between CABG and PCI treatment.
Second, because of the small sample size of the subgroups, all the results of this analysis are
solely intended to be observational and hypothesis generating. Third, diabetic status of patients
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was confirmed at the beginning of the study; subsequent diagnosis of diabetes during the course
of the study was not recorded.
Kappetein et al.[21], conducted a five-year follow-up of the SYNTAX trial, dedicated
solely for diabetic participants. Through classification of patients by their diabetes status, the
study successfully came up with remarkable results. In both diabetic and non-diabetic groups, the
MACCE rate after PCI always exceeded CABG (46.5% vs. 29.0%, 34.1% vs. 26.3%,
respectively). The combined rate of death from all-causes, nonfatal MI, and nonfatal stroke in
diabetic group and non-diabetic group are similar. There was an increased repeat
revascularization risk occurred among PCI patients, compared with CABG patients in both
diabetics (HR=2.75, 95%CI, 1.78-4.24) and non-diabetics (HR=1.82, 95% CI, 1.39-2.38).
Therefore, the difference in clinical outcomes between PCI and CABG was more noticeable in
diabetic group, compared with non-diabetic group. Patients who underwent CABG shared
similar outcome despite their diabetic status. In contrast, diabetic patients who underwent PCI
had pronouncedly worse clinical outcomes than non-diabetic patients with same procedure. In
this study, the diabetic subgroup was randomly stratified and equally distributed into CABG and
PCI group. The small sample size did not ensure adequate power of this subgroup analysis and
therefore, the result could only be viewed as hypothesis generating.
The CARDia trial by Kapur et al. [22], conducted the first trial to compare between PCI
and CABG specifically on patients with diabetes and multivessel CAD called the CARDia
(Coronary Artery Revascularization in Diabetes) trial. The hypothesis of the study was that PCI
could overcome CABG to become the optimal revascularization strategy for diabetic patients. A
total of 600 diabetics were recruited and randomly assigned into to group to undergo either PCI
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or CABG. Data were collected and analyzed at 30 days, six month, one year, two year, and five
year. Primary endpoint was the sum of death from all-cause, MI, and stroke rate at one year,
which was estimated about 9% on the PCI arm and about 12.5% on the CABG arm [18]. Using
PASS 2000 software and a sample size of 300 patients for each control (CABG) and
experimental (PCI) groups, the study achieved 80% power at a 5% significance level.
At one-year follow-up, Kapur et al.[23], detected that the combined rate of death, MI and
stroke in the PCI exceeded that in the CABG group (13.0% vs. 10.5%, respectively) [19].
Critically, patients underwent PCI confronted much higher chance to repeat a revascularization,
compared to CABG patients (11.8% vs. 2.0%, respectively) [19]. In the subgroup of triple-vessel
disease (60% of all patients), the combination of death from all-cause, nonfatal MI and nonfatal
stroke transpired in 15.2% of PCI patients vs. in 11.0% of CABG patients [19]. Meanwhile, the
subgroup of two-vessel disease experienced a contrast trend (9.8% in CABG patients vs. 8.9% in
PCI patients). The trend of stroke rate still favored PCI (0.4%) compared with CABG (2.8%).
The study utilized the Canadian Cardiovascular Society to examine the angina pectoris relief on
participants. Patients in CABG group were less likely to have angina and the trend was observed
in all CCS class of angina (p<0.001). Although PCI cannot beat CABG in the revascularization
of diabetic patients even with the drug-eluting stent, it showed no inferior compared to CABG in
1-year endpoints. The CARDia trial is the first prospective randomized trial to compare between
PCI and CABG on diabetic patients. Hence, although the study was terminated early due to the
withdrawal of participants, the result of CARDia significantly contributed for this paper. Longterm follow-up is required to provide a definitive answer for this long-established debate.
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Farkouh et al.[24], conducted a multicenter randomized trial called The Future
revascularization Evaluation in patients with Diabetes mellitus: Optimal management of
Multivessel disease (FREEDOM) Trial to determine the exceptional approach for
revascularization in patients with DM. From 2005 to 2010, 1900 DM, angiographically
confirmed with multivessel CAD patients were enrolled and divided into two groups of either
CABG or PCI using drug-eluting stent (DES). Patients were scrutinized for 30 days, one year
and annually up to five years. The study had two significant outcomes. The primary outcome
was the combination of death from any cause, nonfatal MI and nonfatal stroke at five year of
follow-up [20]. The second outcome appraised the rate of MACCE at one-year of post
randomization. Other outcomes measured rate of death for all-cause including cardiovascular
mortality at one, two, and three year of post-randomization, quality of life at 30 days, one and
three year follow-up, cost-effectiveness. This trial found that all-cause mortality at five years was
2.66% and 18.7% in the CABG group and in the PCI group, respectively. This absolute
difference of 7.9 percentage points (95% CI, 3.3 to 12.5) demonstrated the superiority of CABG.
In addition, the benefit of CABG was illustrated by the decreased rate of MI at five years
(p<0.01). However, the five years percentage of stroke of CABG group (52%) surpassed that of
PCI group (22%) (p=0.03) [20]. Moreover, the study recognized a disparity in the rates of
MACCE at one year after the procedure between CABG group (11.8%) and PCI group (16.8%)
(p=0.004) [21]. The study had two compelling limitations. First, because of the limited
prevalence of subgroups, the statistical power was not sufficient to detect the interactions
between subgroups. Second, the trial was not blinded, and patients could receive different
method of treatments during long-term follow-up period. Despite those potential biases, the long
duration of patient’s follow-up with the median of 3.8 years, the objective adjudication of the
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outcomes, the variability of participants’ background strengthened this important study. The
result of this trial was a reflection of real-life practice and can be wildly applied in diabetic
patients with multivessel CAD.
Farkouh et al. [25], continued their work by conduct a follow-up study of their
FREEDOM trial, centralizing on the long-term survival rate of patients with DM after mutivessel
revascularization. They successfully persuade enrolling centers and patients from their previous
FREEDOM trial to engage in this follow-up study with median of 7.5 years. According to LongTerm Survival Following Multivessel Revascularization in Patients with Diabetes: The
FREEDOM Follow-On Study, of total 314 deaths during the entire study, the all-cause mortality
rate in PCI group outweighed that of CABG group (24.3% vs. 18.3%, respectively).
Furthermore, statistical analysis illustrated a significant decrease in numbers of MI (eight events
versus ten events) and stroke (three events versus five events) in the CABG group comparing to
the PCI group. These results endorse that CABG should be the preferable revascularization
strategy for DM patients. Although this extended follow-up only recruited 49.6% of the original
population of the FREEDOM trial, it did not create significant differences between cohorts with
or without extended follow-up. Therefore, the loss of initially enrolled patients did not greatly
affect long-term survival. After the FREEDOM trial, multiple new generations of stents have
been introduced into practice and the results of this trial were limited in interpreting this fact.
Meanwhile, the change in PCI platforms did not greatly influence the advantage of CABG over
PCI in long-term survival rate.
Although the FREEDOM trial provided robust evidence of using CABG over PCI in
multivessel revascularization of DM patients, Tam et al.[26], found the need to examine this
result and its application on a larger scale. From October 2008 to December 2018, a retrospective
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analysis named Long-Term Survival After Surgical or Percutaneous Revascularization in
Patients With Diabetes and Multivessel Coronary Disease recruited 14,235 diabetic and
angiographically confirmed of two-vessel or three-vessel CAD patients, in which 4,519 patients
underwent PCI and 9,716 patients were treated with CABG. Data analysis displayed that PCI
were significantly younger, more likely female, and had less severe CAD. Propensity score
matching, which relied on 23 baseline covariates including age, sex, race, pulmonary and renal
disease, cardiac comorbidities, NYHA classification, socioeconomic status, etc., generated 4,301
patients-pairs. Critically, the study reported no meaningful divergence in early deaths between
PCI group (2.4%) and CABG group (2.3%) (Absolute risk difference [ARD]=0.12, p=0.721)
[23]. At eight year follow-up, all cause of mortality of PCI acquired 27.0%, which outstripped
that of CABG group with solely 19.4% (Hazard ratio [HR]: 1.39). The study accessed
independently the components of MACCE and was able to achieve multiple important results. It
was noticeable that the incidence proportion of MI accounted for 7.2% after CABG compared
with 16.4% in the PCI group (HR: 2.32). The chance to repeat revascularization tripled for
patients undergoing PCI (HR: 3.65). Crucially, although the findings of this study were
consistent with that of the FREEDOM trial, Tam et al., were capable to approach patients with
left main disease. In addition, the heart of the study is to utilize the propensity score matching to
establish more balanced groups and to eliminate any potential bias. In conclusion, this study
reinforced that CABG is a better surgical procedure for multivessel CAD in diabetic patients.
The FREEDOM trial is the largest trial to compare PCI and CABG in revascularization
of patient with diabetes and multivessel CAD, which screened a total of 32,966 patients for
eligibility. The study also used contemporary techniques and optimal post-procedure medicine
treatment, compared with previous studies. However, Bansilal et al. [27], inspected the typical
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features of the subjects participated in the FREEDOM trial and launched a comparison with
other trials with similar targeted patients to verify its reliability. According to The Future
REvascularization Evaluation in patients with Diabetes mellitus: optimal management of
Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry, the
mean age of this randomized cohort was 63.1±9.1 years old and 29% of enrolled subjects were
female. The majority of them (83%) had angiographic three-vessel CAD with median diabetes
duration of 10.2±8.9 years. Almost all of them have hypertension (mean systolic blood pressure=
133.7±19.8 mmHg) and hyperlipidemia (mean LDL= 92.7±36.3 mg/dl). A large percentage of
participants had tobacco exposure (55%) and obesity (42%). The mean HbA1C of the study was
78±1.7 mg/dl with 32% of recruited patients being prescribed insulin therapy. These clinical and
angiographic traits of participants of the FREEDOM trial were comparable to those from other
studies including Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2-D),
Coronary Artery Revascularization in Diabetes (CARDia), SYNTAX, BARI, etc. Therefore,
authors concluded that the FREEDOM trial was adequate to provide a precise answer to the
long-term debate on the optimal revascularization strategy for patients by dedicating to high-risk
diabetic patients only.
Magnuson et al.[28], weighted up the cost effectiveness of PCI vs. CABG in patients
with diabetes and multivessel CAD by conducting a study, which analyzed results from
FREEDOM trial. In-person evaluations were administered at one month, six months, and 12
months of post-procedure and annually up to five years to estimate the medical care cost of 1900
patients participated in the FREEDOM trial. Cost-effectiveness of percutaneous coronary
intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus
and multivessel coronary artery disease: results from the FREEDOM trial determined two
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exclusive outcomes. Although PCI has a higher initial procedure cost due to exorbitant price of
stents and other devices, the primary outcome revealed that the total cost for the index
hospitalizations for CABG exceeded that for PCI, which was attributed mostly to longer hospital
stay and physician cost. Secondly, CABG remains the exceptionally cost-effective
revascularization strategy for patients with DM and multivessel CAD by reason of following
factors. After the first five years of post-procedure, CABG profitably reduced follow-up costs up
to $1,672/year (95% CI, $942 to $2,403). Further, a rise in quality-adjusted life expectancy of
0.663 QALYs (95% CI, 0.177 to 1.132) was detected in the study. Finally, CABG extended life
expectancy with an average of 0.794 years with a distinguished gain in incremental costeffectiveness ratios of $6,791/life year .
Although the FREEDOM trial strongly demonstrated the superiority of CABG in terms
of long-term survival rate and risk of MACCE, Abdallah et al.[29], felt the necessity for evaluate
the health status from the patient’s point of view. The baseline health status of 1880 patients
from the FREEDOM trial was examined with following factors: angina frequency (AF), physical
limitations (PL), and quality of life (QOL) domains of the Seattle Angina Questionnaire (SAQ).
Patients would rate each factors by utilizing a scale from zero to 100 points. SAQ-AF of CABG
group at one year and two years follow-up was marginally higher than that of PCI group (mean
difference 1.0 and 1.3 points). However, at three years of post-procedure, there was not
significant difference in angina alleviation between those two groups. Likewise, the scores for
PL and QOL subscales at one year follow-up were meaningfully greater in patients undergoing
CABG, with mean differences 2.0 points and 1.9 points, respectively [26]. In contrast, the study
found no compelling distinct in SAQ-PL and SAQ-QOL scores between two groups of patients
after two years of procedure, which suggested that the benefit of CABG in terms of quality of
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life and health status was not clinically significant. From one month to five years after the
procedure, both PCI and CABG successfully improved basic health status of patients with
diabetes and CAD disease, but the comparison did not favor any of these procedures.
According to Comparative efficacy of coronary artery bypass surgery vs. percutaneous
coronary intervention in patients with diabetes and multivessel coronary artery disease with or
without chronic kidney disease, up to 25% of diabetic patients experienced some degree of renal
impairment [30]. Furthermore, both PCI and CABG contribute risk factors to develop acute
kidney injury (AKI) on diabetic patients. Arbel et al.[31], conducted an analysis based on results
from the FREEDOM trial to determine the incidence of AKI on diabetic patients undergoing
whether PCI or CABG. As a result, 12.3% participants developed AKI after procedure and more
frequently in CABG group, accounting for 15.6%. Another crucial conclusion of that AKI
occurring at 5 years of post-procedure associated with higher risk of MACCE (34.6% vs. 20.5%,
respectively). However, neither CABG nor PCI has a significant relevance with AKI (p=0.89),
which suggested that the two methods of revascularization have equal risk in causing AKI.
Quintar et al. [32], developed a personal prediction tool to guide diabetic and multivessel
CAD to determine their optimal revascularization strategy by using anticipated five-year MACE
and one-year angina post- PCI and CABG. Individualizing Revascularization Strategy for
Diabetic Patients with Multivessel Coronary Disease used SAQ to measure five different
elements of health status in FREEDOM trial’s participants including: angina frequency, angina
stability, quality of life, physical limitation, and treatment satisfaction. The MACE model
considered numerous clinical variables such as age, sex, race, obesity, peripheral vascular
disease, renal impairment, cardiac and pulmonary comorbidities, insulin therapy, etc. and the
treatment interactions with history of tobacco exposure. Aging, prior MI or cerebrovascular
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event, insulin therapy, lower LVEF, lower eGFR are the factors contributed to the recurrence of
MACE. Essentially, patients with history of tobacco exposure who underwent CABG had a
lower risk of MACE compared with PCI (c-statistic of 0.65). Patients who were female, had
angina at baseline and lower hemoglobin were more likely to report a MI at one year. Overall, in
the two predicted models of the study showed that PCI never can beat CABG. Hence, CABG
proved its supremacy for MACE, especially in smoking patients (100%).
Integrating the Synergy between percutaneous coronary intervention with Taxus and
Cardiac Surgery (SYNTAX) score into practice: use, pitfalls, and new directions conceded the
validity of SYNTAX score in pinpointing high-risk patients and guiding the decision process
between CABG and PCI on each patient [33]. Esper et al.[34], conducted an analysis based on
the FREEDOM trial, aiming to assess the utility of SYNTAX score on patients with diabetes and
multivessel CAD.

SYNTAX score in

patients with Diabetes undergoing coronary

revascularization in the FREEDOM trial retrospectively calculated the SYNTAX of each
participant of the FREEDOM trial and release remarkable conclusions. Despite having a low,
intermediate or high SYNTAX score, PCI patients always have higher incidence of MACCE
compared with CABG patients (low SYNTAX score: 36.6% vs. 25.9%; intermediate SYNTAX
score: 43.9% vs. 26.8%; high SYNTAX score: 48.7% vs. 29.7%) [31]. In patients with
intermediate SYNTAX score, PCI group had higher incidence rate of death from all-causes,
nonfatal MI, and nonfatal stroke than CABG group (27.2% vs. 17.7%) [31]. There were not
similar trends observed in the low and high SYNTAX score group. SYNTAX score was
confirmed as an independent risk factor for MACCE and incidence rate of death from all-causes
only on PCI group. Therefore, SYNTAX score should not be adopted as a tool for the choice of
revascularization strategy on patients with diabetes and multivessel CAD.
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Aggarwal et al.[35], emphasized the dominance of the FREEDOM trial in the long-term
debate over the most advantageous revascularization for diabetic patients with multivessel CAD
by comparing it with previous studies with similar research question. The study used the ARTS
trial and the ERACI II trial as studies of PCI with bare-mental stents vs. CABG to compare with
the FREEDOM trial. The downside of these former studies was the lack of glycoprotein IIb/IIIa
inhibitors in PCI to reduce the mortality rate. Additionally, bare-metal stents associated with an
elevated rate of restenosis, compared with drug-eluting stents used in the FREEDOM trial. Being
the first trial to compared PCI-DES and CABG, the ARTS II had its limitations of a nonrandomized trial in which surgeons can chose patients for PCI-DES. The selection bias became
the main cause why the FREEDOM trial surpassed ARTS II. SYNTAX successfully randomly
recruits two groups of diabetic and multivessel patients who have been revascularized by either
CABG or PCI-DES. On the other hand, SYNTAX solely examined the MACCE rate, which is
significant higher in PCI-DES group, while disregarding the survival rate. Both CARDIa trial
(Coronary Artery Revascularization in Diabetes) and VA-CARDS (Veteran Affairs Coronary
Artery Revascularization in Diabetes) were terminated early due to the loss of initial enrollment.
Overall, the FREEDOM trial is a millstone trial contributes significantly to the research of
revascularization method on diabetic patient. As its results, CABG was confirmed as the
preferable procedure since it bypasses all vulnerable plaques and fix heavy calcification.
Several previous studies suggested that CABG was associated with higher risk of postprocedure stroke, compared with PCI. Head et al.[36], conducted an analysis of 11 randomized
trials to evaluate the post-procedure and post-randomization stroke rate and its impact on
mortality rate. In total of 11,518 patients participated in those 11 trials, 5,522 patients were
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treated with CABG whereas 5,843 patients underwent PCI. The cumulative stroke rate at 5-years
follow-up of CABG group exceeded that of PCI group (3.2% vs. 2.6%, respectively). The rate of
stroke at 30 days showed similar trend when stroke occurred in 0.4% patients randomized to PCI
and in 1.1% patients randomized to CABG (HR 0.33). Interestingly, non-diabetic patients who
underwent CABG had lower rate of stroke at 5-year compared with non-diabetic PCI patients
(2.4% vs. 2.6%, respectively). Meanwhile, the rate of stroke at 5-year of diabetic patients was
significantly higher in CABG group vs. PCI group (4.9% vs. 2.6%, respectively). The study
confirmed that diabetes should be considered as a risk factor of stroke in CABG arm. Stroke
occurrence remarkably impacted mortality rate. For instance, patients who experienced stroke in
30 days of post-procedure had significant higher mortality rate, compared with patients who have
not, despite their revascularization strategy. In CABG group, stroke patients had 41.5% mortality
rate, compared with 8.9% in non-stroke patients. Similarly, in PCI group, stroke patients had
45.7% mortality rate and non-stroke patients had 11.1%. According to Head et al.[36], rate of
stroke should be included in the decision progress on the optimal revascularization strategy for
patients.
All previous studies mentioned in this paper recruited diabetic patients despite their type.
Nyström et al.[37], conducted an observational cohort study to compare PCI vs. CABG
specifically on patients with DM type I and multivessel CAD. From 1995 to 2013, a total of 683
DMI patients who underwent CABG and 1,863 DM type I patients who underwent PCI were
recruited and observed during a mean period of 10.6 years. The mortality rate of CABG group
was 53.3%, exceeded that of PCI group, which accounted for 44.6%. Meanwhile, at one-year
follow-up, the absolute risk of death in patients who underwent PCI (5.0%) was significantly
higher than that in patients who underwent CABG (0.7%). The similar trend was observed at two
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years (8.3% in PCI group vs.1.2% in CABG group) and at 5 years (18.6% in PCI group vs. 6.4%
in CABG group). Cause of death in PCI patients was more likely attributed to coronary heart
diseases (HR 1.45, 95%CI, 1.21-1.74). In terms of the adjusted risk for and the frequency of
repeated revascularization, PCI group always beat CABG group through years of observation
(20.1/100 person-years vs. 1.9/100 person-years, respectively). The rate and adjusted risk of
myocardial infarction displayed identical trend (4.6/100 person-years vs. 2.7/100 person-years,
respectively). At 30 days of post-procedure, the rate of stroke in CABG patients surmounted that
in PCI patients (1.9% vs. 0.8%, respectively). On the other hand, long-term adjusted risk of
stroke did not reveal any significant difference between those two groups.

Discussion:
Diabetes mellitus (DM) is considered as a sturdy independent risk factor for multivessel
CAD due to the combinations of several pathophysiology including prothrombotic and
proinflammatory states, endothelial dysfunction, and metabolic disorders. When it comes to
revascularization strategy on this specific group, only two treatment methods were
acknowledged: CABG and PCI. The evolution of stent technology has undeniably improved the
clinical outcomes of patients underwent PCI. The goal of this paper is to examine whether PCI
has successfully displayed non-inferiority to CABG in the treatment of diabetic and multivessel
CAD patients.
The ARTS-I trial and its follow-up analysis studies compared PCI with bare-metal stents
vs. CABG based on short- and long-term clinical outcomes such as the MACCE rate, the
combined death/MI/stroke rate, and the risk of repeated revascularization. CABG was shown to
be superior compared to bare-metal stenting in every endpoint of the trial. The study also
identified DM as an independent risk factor for restenosis and repeated revascularization of the
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PCI arm. This is the oldest study that was included in this paper. As the modern DES evolve and
reduced cost becomes the only reason to choose bare-metal stents over DES, the ARTS-I trial
contributes historically to the topic.
The ARTS-II trial and its follow-up analysis studies demonstrated the contribution of
DES-PCI to clinical outcomes, especially the short-term ones. DES-PCI was marginally
comparable to CABG in the MACCE rate and combined death/MI/stroke rate at one year and
three year follow-up. However, CABG surpassed PCI in every clinical outcome at five years
follow-up, except for stroke rate. Again, the diabetic subgroup had significant high repeated
revascularization risk compared with the non-diabetic group. Although the ARTS-II cannot
prove that PCI-DES is superior to CABG in the treatment of multivessel CAD on DM patients,
this study remains a millstone in interventional cardiology. Hence, the study successfully
demonstrated that the use of DES significantly improved the clinical outcomes, compared with
the bare-metal stents. Therefore, PCI-DES is a safe and efficacious choice for DM patients with
multivessel CAD. Being a non-randomized study and using the ARTS-I population as historical
control, statistical adjustments needs to be performed properly to eliminate potential biases and
ensure the power of the ART-II trial. Therefore, the debate over the optimal revascularization
strategy for DM patients with multivessel CAD still needs further investigations.
The SYNTAX trial was the first randomized trial, which compared DES-PCI and CABG
on multivessel CAD patients. This trial strengthened the benefit of DES on both short- and longterm clinical outcomes. At one year and five year follow-up, PCI group had similar combined
rate of death/MI/stroke compared to CABG group despite diabetic status. In contrast, PCI
showed inferiority to CABG regarding elevated MACCE rate and repeated revascularization
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risk. The primary endpoint of the SYNTAX trial cannot meet because the lack of enrollment.
Therefore, its results only have observational and “hypothesis-generating” meaning.
The CARDia trial was the first comparison study between DES-PCI and CABG targeting
patients with DM and multivessel CAD. The hypothesis of the study was that PCI-DES is
noninferior to CABG, especially on the treatment of those specific patients. However, the results
of the study failed to support this hypothesis and CABG remains superior to DES-PCI in the
revascularization of multivessel CAD on DM patients. Because long-term follow-up study on
this trial cannot be conducted due to the loss of initial enrollment, the results of this trial solely
have observational and “hypothesis-generating” meaning.
The FREEDOM trial was the largest multicenter, randomized trial that was conducted to
compare between DES-PCI and CABG in diabetic and multivessel CAD patients. The results of
the trial and its follow-up studies affirmed that CABG remains the optimal revascularization for
this specific patient population. CABG group had pronouncedly lower combined death/MI/stroke
rate at five years follow-up and lower MACCE rate at one year follow-up, compared with PCI
group. In the long run, CABG was more cost-beneficial despite its extravagant initial cost.
CABG and PCI shared similar risk of development of AKI after procedure. Furthermore, chronic
kidney disease did not have great impact on the MACCE rate regardless revascularization
method. One significant drawback of CABG is the soaring stroke rate post-procedure. Both rate
of stroke at 30 days and cumulative rate at five years follow-up of CABG group exceeded that of
PCI group.
The credibility and validity of the FREEDOM trial has ensured a certain answer
regarding the optimal revascularization strategy for patients with diabetes and multivessel CAD.
However, in the real world practice, the implication of the FREEDOM trials showed some
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limitations. For example, according to Management of acute coronary syndromes in patients
with diabetes: implications of the FREEDOM trial, only 30% participants of the FREEDOM trial
had acute coronary syndrome (ACS) while 70% patients with ACS received PCI at all the
Australian catheterization laboratories. Moreover, the exclusion criteria of the trial included
patients who experienced STEMI, elevated creatinine kinase and/or CM-MB 72 hours before
randomization. Therefore, future research should target the emergent reperfusion strategy for
STEMI on patients with diabetes and multivessel CAD. Another noticeable point is that modern
antiplatelet agents such as prasugrel or ticagrelor were not yet introduced in the FREEDOM trial.
According to Prasugrel versus clopidogrel in patients with acute coronary syndromes, prasugrel
had reduced stent thrombosis by 52%, compared to clopidogrel, especially on DM patients [39].
Furthermore, as the interventional cardiology evolves, newer generation of DES has been
introduced into practice including the new Resolute Integrity Zotarolimus-eluting stent, which
was approved specifically for the use on DM patients. Those inventions can significantly
interfere with the implications of FREEDOM trials in real-life practice. Hence, although CABG
appears to be the treatment of choice for DM patients with multivessel CAD, further
investigations are necessary as the difference in clinical outcomes after PCI and CABG narrows
down.

Conclusion:
Abundant randomized trials and follow-up analysis were conducted to detect the
definitive answer for the debate on whether PCI or CABG is the optimal revascularization
strategy for patients with DM and multivessel CAD. By aggregating valid and legitimate data
from those articles, this review aimed to examine the short- and long- term clinical outcomes
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after either procedure. The scope of review mostly evaluated of the mortality rate from all-cause,
nonfatal MI and stroke rate, the MACCE rate, and the repeated revascularization risk, which
were collected at various points of post-procedure and post-randomization. In the bare-mental
area, the ARTS-I trial and other follow-up analysis demonstrated that CABG beat PCI in all
short- and long-term clinical outcomes. Other analysis that targeted the diabetic subgroup of the
ARTS-I confirmed that diabetes is an independent risk factor to increase the MACCE rate in PCI
patients. When DES was applied broadly, the ARTS-II and SYNTax trials, proved that PCI was
merely marginal to CABG in terms of early clinical outcomes, especially the mortality and the
MACCE rate. However, other analysis revealed that diabetes status contributed to the elevated
mortality rate and MACCE rate in PCI group. The CARDia trial and the FREEDOM trial, which
targeted solely diabetic patients with multivessel CAD, concluded that CABG remains the
optimal revascularization for this specific group of patients.
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Appendix A

Electronic databases
searched with PubMed
and specific keywords.
Potentially relevant
studies identified,
includind
duplcates(n=438)

Potentially appropriate
studies after screening
titles and abstracts.
Downloaded full-text
studies (n=57)

Studies that meet the
specific criteria (n=23)

Excluded studies after
manually screening titles
and abstracts with specific
criteria like “PCI”, “CABG”,
“Multivessel CAD”,
“diabetes” (n=381)

Excluded studies after
reading the full-text
studies. Found that
studies did not meet
specific criteria (n=34)

Screening of reference lists
and citations to identify
more studies that are
relevant to the scope of
review (n=26)

Figure 1: Flow diagram of Literature search and Selection process
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REFERENCE AND PURPOSE

SUBJECTS

#

Sample design

Purpose

Intervention

CONCLUSION

Control

Based on death/MI/Stroke rate
and repeated revascularization
risk, CABG is superior to PCI.
Similar quality of life. CABG has
higher cost of treatment.

VARIABLES

Year data collected

CABG

PCI with Baremetal stents

DATA

1997-1999

PCI with Baremetal stents

Multivessel diabetic patients
treated with PCI had worse one
year clinical outcomes than
patients treated with CABG and
nondiabetic patients treated with
stenting.CABG has higher cost of
treatment. Diabetes mellitus(DM)
is an independent risk factor for
worsened clinical outcomes

CABG

Subjects characteristics

Year published

1205

Author(s), Title, Journal

2001

Multicenter, randomized, unblinded
Patients with stable angina or
patient assessor. Death, MI,and
unstable angina or silent
stroke rate, repeated revascularization
ischemia and at least two new
risk at 30 days, six months, 12
lesions located on different
months.Quality of life(EuroQoL).
vessels
Initial cost of procedure and cost of
treatment at 12 months.

CABG

No significant difference in
death/MI/stroke rate. CABG has
smaller risk of repeated
revascularization than PCI.
1997-2004

1997-1999

PCI with Baremetal stents

1205

Patients with stable angina or
Multicenter, randomized, unblinded
unstable angina or silent
patient assessor. Death, MI,and
ischemia and at least two new
stroke rate, repeated revascularization
lesions located on different
risk at five years.
vessels

The Death/MI/Stroke rate of the
ARTS-II trial was lower than
ARTS-I PCI and similar to ARTS
PCI with
I CABG. CABG has lower
Sirolimus-eluting
repeated revascularization risk
stents
than both PCI with sirolimiseluting stents and bare-metal
stents.
CABG and
bare-metal
stents PCI

CABG and
bare-metal
stents PCI

2003-2004

2003-2005

The Death/MI/Stroke rate of the
ARTS-II trial is similar to ARTSPCI with
I CABG in diabetic patients.
Sirolimus-eluting
CABG has lower repeated
stents
revascularization risk. DM is is an
independent risk factor for
worsened clinical outcomes.

Multicenter, randomized, unblinded
Similar basic characteristics
patient assessor. Death, MI,and
with ARTS-I trial, at least onestroke rate, repeated revascularization
third has three-vessel disease
risk at 30 days and one year.

367

Similar basic characteristics Multicenter, randomized, unblinded
with ARTS-I trial, at least onepatient assessor. Death, MI,and
third has three-vessel disease, stroke rate, repeated revascularization
plus DM type I or II
risk one year.

1812

Multicenter, randomized, unblinded
patient assessor. Death, MI,and
stroke rate, repeated revascularization
risk at one year. Total cost of
treatment at one year.

Compare betwee baremetal stent PCI and
CABG for the treatment
of multivessel CAD
based on clinical
outcomes, quality of life
and cost-effectiveness.

Serruys PW, Unger F, Sousa JE,
et al. Comparison of coronaryartery bypass surgery and stenting
for the treatment of multivessel
disease. N Engl J Med.

2001

Compare between baremental stent and CABG
based on clinical and
economic impact on
diabetic subgroup of the
ARTS trial
208

2005

Compare between
CABG and bare-metal
stent PCI for the
treatment of multivessel
CAD based on 5 years
clinical outcomes.

Serruys PW, Ong AT, van
Herwerden LA, et al. Five-year
outcomes after coronary stenting
versus bypass surgery for the
treatment of multivessel disease:
the final analysis of the Arterial
Revascularization Therapies Study
(ARTS) randomized trial. J Am
Coll Cardiol.

Serruys PW, Ong AT, Morice
MC, et al. Arterial
Revascularisation Therapies Study
Part II - Sirolimus-eluting stents for
the treatment of patients with
multivessel de novo coronary
artery lesions. EuroIntervention.

Similar basic characteristics
with ARTS-I trial plus DM
type I or II

2005

Compare between
sirolimis-eluting stents
PCI and CABG for the
treatment of multivessel
CAD using the CABG
group of the ARTS-I
trial as historical control
group.

Abizaid A, Costa MA, Centemero
M, et al. Clinical and economic
impact of diabetes mellitus on
percutaneous and surgical
treatment of multivessel coronary
disease patients: insights from the
Arterial Revascularization Therapy
Study (ARTS) trial. Circulation.

2006

Compare between
sirolimis-eluting stents
PCI vs. CABG and baremetal stent for the
treatment of multivessel
CAD on the diacbetic
subgroup of the ARTS-I
and ARTS-II trials
based on one-year
clinical outcomes.

Macaya C, García-García HM,
Colombo A, et al. One-year results
of coronary revascularization in
diabetic patients with multivessel
coronary artery disease.Sirolimus
stent vs. coronary artery bypass
surgery and bare metal stent:
insights from ARTS-II and ARTSI. EuroIntervention.
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COMMENTS
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2010

2011

2006

2008

Compare between
paclitaxel-eluting stents
PCI and CABG for the
treatment of multivessel
CAD on diabetic and
nondiabetic patients
based on clinical
outcomes at one year

Compare between
paclitaxel-eluting stents
PCI and CABG for the
1800 (452
treatment of multivessel
DM; 258
CAD on diabetic or
metabolic
metabolic syndrome
syndrome)
patients based on
clinical outcomes at
three years.

Compare between
paclitaxel-eluting stents
PCI and CABG for the
treatment of multivessel
CAD based on clinical
outcomes

Three-year follow-up of
the ARTS-II trials,
compare
revascularizations
strategies on diabetic vs.
non-diabetic patients.
1812

2013

Compare between
paclitaxel-eluting stents
PCI and CABG for the
treatment of multivessel 1801 (452
CAD on diabetic
DM)
patients based on
clinical outcomes at five
years

510

1800 (452
DM)

1800

2005

PCI versus CABG in DM patients

Daemen J, Kuck KH, Macaya C, et
al. Multivessel coronary
revascularization in patients with
and without diabetes mellitus: 3year follow-up of the ARTS-II
(Arterial Revascularization
Therapies Study-Part II) trial. J Am
Coll Cardiol .

Ong ATL, Serruys PW, Mohr FW,
et al. The SYNergy between
percutaneous coronary intervention
with TAXus and cardiac surgery
(SYNTAX) study: design,
rationale, and run-in phase. Am
Heart J.

Mack MJ, Banning AP, Serruys
PW, et al. Bypass versus drugeluting stents at three years in
SYNTAX patients with diabetes
mellitus or metabolic
syndrome. Ann Thorac Surg .

Banning AP, Westaby S, Morice
MC, et al. Diabetic and
nondiabetic patients with left main
and/or 3-vessel coronary artery
disease: comparison of outcomes
with cardiac surgery and paclitaxeleluting stents. J Am Coll Cardiol .

Kappetein AP, Head SJ, Morice
MC, et al. Treatment of complex
coronary artery disease in patients
with diabetes: 5-year results
comparing outcomes of bypass
surgery and percutaneous coronary
intervention in the SYNTAX trial.
Eur J Cardiothorac Surg

Kapur A, Malik IS, Bagger JP, et
al. The Coronary Artery
Revascularisation in Diabetes
(CARDia) trial: background, aims,
and design. Am Heart J.

Is optimal PCI not
inferior to modern
CABG as
revascularization
strategy fpr diabetics
with multivessel or
complex single vessel
CAD?

CABG and
bare-metal
stents PCI

CABG

2003-2008

2004-2006

CABG

Multicenter, randomized, unblinded
Similar basic characteristics
patient assessor. Death, MI,and
with ARTS-I trial, at least onestroke rate, repeated revascularization
third has three-vessel disease
risk at three year.

Multicenter, randomized, unblinded
patient assessor. Death, MI,and
stroke rate, repeated revascularization
risk. Using SAS system for data
analysis. Student t-test and Chisquare test are used to compare
variables.

2006-2011

De novo three-vessel disease
or left main disease

Multicenter, randomized, unblinded
patient assessor. Death, MI,and
De novo three-vessel disease
stroke rate, repeated revascularization
or left main disease with DM
risk at three years. Using SAS system
type I or II or metabolic
for data analysis. Student t-test and
syndrome
Chi-square test are used to compare
variables

CABG

Patients with DM has higher rate
of death/MI/Stroke and repeat
revascularization in PCI group
than in CABG group.

PCI with sirolimus- eluting stents
is safer than PCI with bare-metal
stents regardless the diabetic
PCI with
status of patients. PCI with
Sirolimus-eluting
sirolimus-eluting stents has
stents
similar clinical outcomes at three
year compared with CABG and is
a valuable alternative.

PCI with
paclitaxel-eluting
stents

CABG

PCI has higher death/MI/stroke
rate and repeat revascularization
PCI with
in both diabetic and nondiabetic
paclitaxel-eluting
groups. CABG is the treatment of
stents
choice for diabetic patients with
multivessel CAD.

Among diabetic patients with
multivessel CAD or complex left
main disease, the death/MI/stroke
rate and the repeated
PCI with
paclitaxel-eluting revascularization risk is higher
after PCI compared with CABG
stents
at three years. CABG is the
revascularization of choice for
those patients
Death/MI/stroke rate is
comparable between PCI and
CABG for diabetic and
nondiabetic groups. The risk of
PCI with
repeated revascularization is
paclitaxel-eluting
higher with PCI among diabetic
stents
patients. PCI is a safe treatment
for diabetic patients with
multivessel CAD

CABG

2006-2010

De novo three-vessel disease
or left main disease

2011-2013

2002-2004

The study is terminated early due
the lack of enrollement.
Howerver, PCI is not superior in
any clinical outcomes findings,
compared with CABG.
PCI with drugeluting stents

Multicenter, randomized, unblinded
patient assessor. Death, MI,and
stroke rate, repeated revascularization
risk. Using SAS system for data
analysis. Student t-test and Chisquare test are used to compare
variables.

Multicenter, randomized, unblinded
patient assessor. Death, MI,and
De novo three-vessel disease stroke rate, repeated revascularization
or left main disease plus DM
risk. Using SAS system for data
type I or II
analysis. Student t-test and Chisquare test are used to compare
variables.

Multicenter, randomized,
prospective, patient-assessor blinded.
Death, MI, stroke rate and repeated
Diabetic patients with
revascularization risk at 30 days, six
multivessel or complex single
months, one year, 2 years, 5 years
vesssel CAD.
(reviewed by the Critical Events
Adjusdication Committee). Using the
intent-to-treat principle and Stata
10.1 for all analyses.
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2020

2019

2012

2010

Is drug-eluting stents
PCI superior to CABG
in treatment of
multivessel CAD on
diabetic patients based
on long-term survival
rate?

Is drug-eluting stents
PCI superior to CABG
in treatment of
multivessel CAD on
diabetic patients?

Is optimal PCI not
inferior to modern
CABG as
revascularization
strategy fpr diabetics
with multivessel or
complex single vessel
CAD at one year followup?

2012

Does the FREEDOM
have an adequate power
to prove that CABG is
superior to PCI for the
treatment of multivessel
CAD on diabetic
patients?

Compare early and longterm outcomes of PCI
vs. CABG in diabetic
patients with
multivessel CAD.

PCI versus CABG in DM patients

Kapur A, Hall RJ, Malik IS, et al.
Randomized comparison of
percutaneous coronary intervention
with coronary artery bypass
grafting in diabetic patients. 1-year
results of the CARDia (Coronary
Artery Revascularization in
Diabetes) trial. J Am Coll Cardiol.

Farkouh ME, Domanski M,
Sleeper LA, et al. Strategies for
multivessel revascularization in
patients with diabetes. N Engl J
Med.

Farkouh ME, Domanski M,
Dangas GD, et al. Long-Term
Survival Following Multivessel
Revascularization in Patients With
Diabetes: The FREEDOM FollowOn Study. J Am Coll Cardiol.

Tam DY, Dharma C, Rocha R, et
al. Long-Term Survival After
Surgical or Percutaneous
Revascularization in Patients With
Diabetes and Multivessel Coronary
Disease. J Am Coll Cardiol.

Bansilal S, Farkouh ME, Hueb W,
et al. The Future REvascularization
Evaluation in patients with
Diabetes mellitus: optimal
management of Multivessel disease
(FREEDOM) trial: clinical and
angiographic profile at study entry.
Am Heart J.

1900

9,716

943

1900

510

Multicenter, randomized, open-label
prospective, patient-assessor blinded.
Health status assessment with Seattle
≥18 years old, DM type I or II,
Angina Questionnaire (19 items;
Multivessel CAD lesions in ≥
score ranges 0-100). Baseline
2 major epicardial vessels and
characteristics of patients were
in ≥ separate coronary artery compared using Fisher exact test for
territories.
categorical variables, Wilcoxon rank
sum test and Student's t-test for
continuous variables. SAS version
9.2 was used for analyses

Multicenter, randomized,
retrospective. Propensity score
matching method is used to minimize
confounding. Student's t test for
normally distributed continuous
DM type I or type II patients, variables, Wilcoxon rank-sum test
angiographic evidenceof twofor non-normally distributed
vessel or three-vessel CAD.
continuous variables, Chi-square test
for categorical variables. All-cause
mortality rate at 30 days and followup annually up to 11.5 years. Longterm death/MI/stroke rate and repeat
revascularization.

≥18 years old, DM type I or II,
Multicenter, randomized, open-label
Multivessel CAD lesions in ≥
prospective, patient-assessor blinded.
2 major epicardial vessels and
All-cause mortality rate follow-up
in ≥ separate coronary artery
annually, median of 7.5 years
territories.

Multicenter, randomized, open-label
≥18 years old, DM type I or II, prospective, patient-assessor blinded.
Multivessel CAD lesions in ≥ Death, MI, stroke rate and repeated
2 major epicardial vessels and revascularization risk at 30 days, one
in ≥ separate coronary artery
year, and annually up to 5
territories.
years.Routine assessment of angina,
neurologic status, cardiac markers.

Multicenter, randomized,
prospective, patient-assessor blinded.
Death, MI, stroke rate and repeated
Diabetic patients with
revascularization risk at 30 days, six
multivessel or complex single
months, one year, 2 years, 5 years
vesssel CAD.
(reviewed by the Critical Events
Adjusdication Committee). Using the
intent-to-treat principle and Stata
10.1 for all analyses.
2002-2007

2005-2010

2005-2019

2008-2017

2005-2010

CABG

CABG

CABG

PCI with drugeluting stents

PCI with drugeluting stents

PCI with drugeluting stents

PCI with drugeluting stents

In diabetic patients with
multivessel CAD, CABG
decreases long-term all-cause
mortality, compared with PCI.
CABG improves MI, stroke and
repeated revascularization rate.

In diabetic patients with
multivessel CAD, CABG
decreases all-cause mortality,
compared with PCI in long-term
follow-up.

CABG is superior to PCI in
reducing rates of death and MI,
with a higher rate of stroke for
patients with diabetes and
advanced CAD.

One year clinical does not show
that PCI is noninferior to CABG.
However, PCI is feasible in
diabetic patients with multivessel
CAD.

CABG

CABG

PCI with drugeluting stents

Characteristics of the randomized
cohort: Mean age 63.1±9.1 years;
29% female; median diabetes
duration 10.2±8.9 years, 83%
three-vessel disease, mean
HbA1C 7.8±1.7mg/dL. The
FREEDOM trial has successfully
recruited a high-risk diabetic
multivessel CAD cohort. The trial
has adequate power to prove tha
CABG is superior to PCI.
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2013

2013

PCI have better impact
on health status among
diabetic patients with
multivessel CAD than
CABG?

Does PCI has better cost
effectiveness in the
treatment of multivessel
CAD on diabetic
patients than CABG?

2019

Examination of the
impact of acute kidney
injury on diabetic
patients with
multivessel CAD
undergoing PCI vs
CABG

2016

2019

Build a risk models of
the heterogeneity of
treatment benefit to
translate the results of
the FREEDOM trial to
individual patients in
clinical practice.

Examination of the
impact of CABG vs.
PCI on cardiovascular
outcomes in diabetic
patients with and
without chronic kidney
disease?

PCI versus CABG in DM patients
Magnuson EA, Farkouh ME,
Fuster V, et al. Cost-effectiveness
of percutaneous coronary
intervention with drug eluting
stents versus bypass surgery for
patients with diabetes mellitus and
multivessel coronary artery
disease: results from the
FREEDOM trial. Circulation.
Abdallah MS, Wang K, Magnuson
EA, et al. Quality of life after PCI
vs CABG among patients with
diabetes and multivessel coronary
artery disease: a randomized
clinical trial: A randomized clinical
trial. JAMA.

Baber U, Farkouh ME, Arbel Y, et
al. Comparative efficacy of
coronary artery bypass surgery vs.
percutaneous coronary intervention
in patients with diabetes and
multivessel coronary artery disease
with or without chronic kidney
disease. Eur Heart J.

Arbel Y, Fuster V, Baber U,
Hamza TH, Siami FS, Farkouh
ME. Incidence, determinants and
impact of acute kidney injury in
patients with diabetes mellitus and
multivessel disease undergoing
coronary revascularization: Results
from the FREEDOM trial. Int J
Cardiol.

Qintar M, Humphries KH, Park
JE, et al. Individualizing
Revascularization Strategy for
Diabetic Patients With Multivessel
Coronary Disease. J Am Coll
Cardiol.

1692

1990(467
chronic
kidney
disease)

1880

1900

Multicenter, randomized, open-label
prospective, patient-assessor blinded.
"As-treated" subgroup analysis.
Glomerular filtration rate is estimated
≥18 years old, DM type I or II,
using Chronic Kidney Disase
Multivessel CAD lesions in ≥
Epidemiology Collaboration
2 major epicardial vessels and
equation. Student's t test for
in ≥ separate coronary artery
continuous variables. Chi- square test
territories.
for categorical variables. The
death/MI/stroke rate at five years.
The rate of chronic kidney disease at
five years.

Multicenter, randomized, open-label
prospective, patient-assessor blinded.
≥18 years old, DM type I or II,
Health status assessed using the agina
Multivessel CAD lesions in ≥
frequency, physical limitations , and
2 major epicardial vessels and
quality of life domains of Seattle
in ≥ separate coronary artery
Angina Questionnaire at one, six, and
territories.
12 months. Score ranges from 0 to
100.

≥18 years old, DM type I or II, Multicenter, randomized, open-label
Multivessel CAD lesions in ≥ prospective, patient-assessor blinded.
2 major epicardial vessels and
Cost were assessed from the
in ≥ separate coronary artery
perspective of the U.S. healthcare
territories.
system. In-trial results

2010-2017

2010-2015

2005-2012

2005-2011

CABG

CABG

CABG

CABG

PCI with drugeluting stents

PCI with drugeluting stents

PCI with drugeluting stents

PCI with drugeluting stents

CABG has higher risk for acute
kidney injury. However, the
impact of acute kidney injury on
the death/MI/stroke rate is
substantial irrespective of
revascularization strategy.

CABG preserves the long-term
risk of death/MI/Stroke on
patients with mild to moderate
chronic kidney disease

CABG provides slightly better
intermediate term health status
and quality of life than PCI at six
months and two years.

CABG has better costeffectiveness compared to PCI
regardless higher initial cost.

CABG

Multicenter, randomized, open-label
prospective, patient-assessor blinded.
The all-cause death/MI/stroke rate at
≥18 years old, DM type I or II,
five years is the primary outcome.
Multivessel CAD lesions in ≥
Glomerular filtration rate is estimated
2 major epicardial vessels and
using Chronic Kidney Disase
in ≥ separate coronary artery
Epidemiology Collaboration
territories.
equation. Acute Kidney Injury was
determined using the AKI network
criteria

2005-2010

PCI is never superior to CABG
and CABG is superior to PCI for
the death/MI/stroke rate in
majority of patients and in all of
patients with history of smoking
1900

PCI with drugeluting stents

Using patient-level data from the
≥18 years old, DM type I or II, FREEDOM trial patients to develop
Multivessel CAD lesions in ≥
models to predict five year rate of
2 major epicardial vessels and death/MI/stroke and one year angina
in ≥ separate coronary artery
after CABG and PCI. Bootstrap
territories.
resampling to internally validate the
model

Table 1: Review Matrix on the Comparison of PCI vs. CABG for the revascularization of multivessel CAD on DM patients (continued)

38

2017

2018

2018

Does PCI with drugeluting stents has better
survival rate than
CABG on patients with
DM type I and
Multivessel CAD?

Does stroke rate after
CABG is higher than
after PCI in patients
with DM and
multivessel CAD?

Is SYNTAX score
important in predicting
future cardiovascular
events in patients with
DM and multivessel
CAD undergoing
CABG vs. PCI?

PCI versus CABG in DM patients

Esper RB, Farkouh ME, Ribeiro
EE, et al. SYNTAX score in
patients with Diabetes undergoing
coronary revascularization in the
FREEDOM trial. J Am Coll
Cardiol.

Head SJ, Milojevic M, Daemen J,
et al. Stroke rates following
surgical versus percutaneous
coronary revascularization. J Am
Coll Cardiol

Nyström T, Sartipy U, Franzén S,
et al. PCI Versus CABG in
Patients With Type 1 Diabetes and
Multivessel Disease [published
correction appears in J Am Coll
Cardiol. 2017 Nov 7;70(19):2462].
J Am Coll Cardiol.
2546

11,518

1900

Multicenter, observational cohort
study. Swedish Web-system for
Enhancement and Development of
DM type I, underwent a first Evidence- based care in Heart disease
multivessel revascularization
Evaluated According to
(involving at least two
Recommended Therapies register,
significantly stenosed coronary
the Swedish Natinal Diabetes
arteries)
Register, the Swedish Natinal Patient
Register to retrieve information. Allcause death/MI/stroke rate, repeat
revascularization.

Randomly assigned to undergo Collaborative individual patient-data
CABG or PCI, Multivessel or pooled analysis of 11 reandomized
Left main CAD, Did not
clinical trials comparing PCI vs.
present with acute MI, PCI CABG. 30 days and five years stroke
using stents, stroke occurs after
rate. Cox proportional hazards
30 days of follow-up.
model.

Using a core laboratory to
≥18 years old, DM type I or II,
retrospectively calculate the Syntax
Multivessel CAD lesions in ≥
score of FREEDOM trial patients.
2 major epicardial vessels and
The death/MI/stroke rate and repeat
in ≥ separate coronary artery
revascularization at fave years are
territories.
endpoints.
2005-2016

2017

1995-2013

CABG

CABG

CABG

PCI with drugeluting stents

PCI with drugeluting stents

PCI with drugeluting stents

PCI has higher all-cause
mortality, MI rate and repeat
revascularization. CABG is
preferrable in patients with
multivessel CAD and DM type I.

Risk of stroke at 30 days at at
five yearsare lower in PCI group
than in CABG group. Patients
who have stroke post-procedure
have significant higher mortality
rate.

The Syntax score is an
independent risk factor for the
death/MI/stroke rate and the
repeat revascularization on PCI
patients only. Ayntax score
should not be used as guide of
choice for revascularization in
diabetic patients with multivessel
CAD.
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